OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

Molecular Therapy

Volumn 6, Issue 4, 2002, Pages 528-536

  Pan, Ping Ying ^a   Zang, Yunjuan ^a   Weber, Kaare ^a   Meseck, Marcia L ^a   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocyte; Gene therapy; Memory T cells; Tumor immunity

Indexed keywords

ADENOVIRUS VECTOR; CD134 ANTIGEN; INTERLEUKIN 12; LYMPHOCYTE ANTIBODY;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ISOLATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; GENETIC CODE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LIVER METASTASIS; LYMPHOCYTE FUNCTION; MEMORY CELL; MOUSE; NONHUMAN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0036799040     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0699     Document Type: Article

References (47)

1. Chen, S. H., et al. (2000). Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2: 39-46, doi 10.1006/mthe.2001.0091.
2. Pham-Nguyen, K. B., et al. (1999). Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer 81: 813-819.
3. Paterson, D. J., et al. (1987). Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 24: 1281-1290.
4. Mallett, S., Fossum, S., and Barclay, A. N. (1990). Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor. EMBO J. 9: 1063-1068.
5. Hintzen, R. Q., de Jong, R., Lens, S. M., and van Lier, R. A. (1994). CD27: marker and mediator of T-cell activation? Immunol. Today 15: 307-311.
6. Miura, S., et al. (1991). Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol. Cell. Biol. 11: 1313-1325.
7. al-Shamkhani, A., et al. (1996). OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26: 1695-1699.
8. Stuber, E., Neurath, M., Calderhead, D., Fell, H. P,, and Strober, W. (1995). Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2: 507-521.
9. Akiba, H., et al. (1999). CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 162: 7058-7066.
10. Maxwell, J. R., Weinberg, A., Prell, R. A, and Vella, A. T, (2000). Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164: 107-112.
11. Gramaglia, I., et al. (2000). The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165: 3043-3050.
12. Vetto, J. T., et al. (1997). Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 174: 258-265.
13. Ramstad, T., Lawnicki, L., Vetto, J., and Weinberg, A. (2000). Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am. J. Surg. 179: 400-406.
14. Weinberg, A. D., et al. (2000). Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164: 2160-2169.
15. Cordaro, T. A., et al. (2000). Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur. J. Immunol. 30: 1297-1307.
16. + T cell adoptive immunotherapy. Immunity 13: 265-276.
17. Melero, I., et al. (1998). Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 costimulatory pathway. Eur. J. Immunol. 28: 1116-1121.
18. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55.
19. Gramaglia, I., Weinberg, A. D., Lemon, M., and Croft, M. (1998). OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161: 6510-6517.
20. Brocker, T., et al, (1999). CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29: 1610-1616.
21. Lane, P. (2000). Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J. Exp. Med. 191: 201-206.
22. Weinberg, A. D., Wegmann, K. W., Funatake, C., and Whitham, R. H. (1999). Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162: 1818-1826.
23. Akiba, H., et al. (2000). Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191: 375-380.
24. Budd, R. C., et al. (1987). Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J. Immunol. 138: 3120-3129.
25. Sprent, J., and Tough, D. F. (1994). Lymphocyte life-span and memory. Science 265: 1395-1400.
26. MacDonald, H. R., Budd, R. C., and Cerottini, J. C. (1990). P9p-1 (Ly 24) as a marker of murine memory T lymphocytes. Curr. Top. Microbiol. Immunol. 159: 97-109.
27. Bennett, S. R., et al. (1998). Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
28. + T-helper and a T-killer cell. Nature 393: 474-478.
29. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and Melief, C. J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
30. Lu, Z., et al. (2000). CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J. Exp. Med. 191: 541-550.
31. Tanaka, H., Demeure, C. E., Rubio, M., Delespesse, G., and Sarfati, M. (2000). Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J. Exp. Med. 192:405-412.
32. Flynn, S., Toellner, K. M., Raykundalia, C., Goodall, M., and Lane, P. (1998). CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188: 297-304.
33. Ohshima, Y., et al. (1998). OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-producing effectors. Blood 92: 3338-3345.
34. Kjaergaard, J., et al. (2000). Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60: 5514-5521.
35. Weatherill, A. R., Maxwell, J. R., Takahashi, C., Weinberg, A. D., and Vella, A. T. (2001). OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cell. Immunol. 209: 63-75.
36. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
37. Hung, K., et al. (1998). The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
38. Cannons, J. L., et al. (2001). 4-1BB ligand induces cell division, sustains survival, and enhances effector function of cd4 and cd8 t cells with similar efficacy. J. Immunol. 167: 1313-1324.
39. De Smedt, T., et al. (2002). Ox4O costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168: 661-670.
40. Smyth, M. J., Godfrey, D. I., and Trapani, J. A. (2001). A fresh look at tumor immuno-surveillance and immunotherapy. Nat. Immunol. 2: 293-299.
41. Bansal-Pakala, P., Gebre-Hiwot Jember, A., and Croft, M. (2001). Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7: 907-912.
42. Jember, A. G., Zuberi, R., Liu, F. T., and Croft, M. (2001). Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med. 193: 387-392.
43. Yoshioka, T., et al. (2000). Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30: 2815-2823.
44. Higgins, L. M., et al. (1999). Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J. Immunol. 162: 486-493.
45. Caruso, M., et al. (1996). Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93: 11302-11306.
46. Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., and Schabel, F. M. (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35: 2434-2439.
47. Martinet, O., et al. (2000). Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J. Natl. Cancer Inst. 92: 931-936.